The CMap analysis of our study found that HDAC inhibitors trichostatin A and vorinostat had a potential therapeutic effect on HCC patients in the high-risk calpain group, which had higher CAPN1 and CAPN2 expression. Here, HDAC9 is linked to hepatocellular carcinoma.